Results 41 to 50 of about 2,328 (144)

Comparative evaluation of QuantiFERON-TB gold in-tube plus for Mycobacterium tuberculosis infection among adolescents in China

BMC Public Health
Summary To our knowledge, this is the first head-to-head study to evaluate QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube, ESAT6-CFP10, and tuberculin skin test among adolescents.
Peng Lu, Leonardo Martinez, Hao Xue, Qiao Liu, Xiaoyan Ding, Jingjing Pan, Hui Ding, Wei Lu, Limei Zhu, Jiangming Wang   +9 more
doaj   +1 more source

Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study

Thorax, 2022
RationaleIn 2016, a new interferon-gamma release assay (IGRA) was introduced, QuantiFERON-TB Gold Plus (QFT-Plus), claimed to have improved sensitivity in active tuberculosis (TB).ObjectivesThis study aimed to determine the performance of QFT-Plus, compared with previous generation IGRAs and the tuberculin skin test (TST), in children with TB in Europe.
Buonsenso, Danilo, Noguera-Julian, Antoni, Moroni, Rossana, Hernández-Bartolomé, Angel, Fritschi, Nora, Lancella, Laura, Cursi, Laura, Soler-Garcia, Aleix, Krüger, Renate, Feiterna-Sperling, Cornelia, Sali, Michela, Lo Vecchio, Andrea, Scarano, Sara, Hernanz Lobo, Alicia, Espiau, Maria, Soriano-Arandes, Antonio, Cetin, Benhur Sirvan, Brinkmann, Folke, Ozere, Iveta, Baquero-Artigao, Fernando, Tsolia, Maria, Milheiro Silva, Tiago, Bustillo-Alonso, Matilde, Martín Nalda, Andrea, Mancini, Margherita, Starshinova, Anna, Ritz, Nicole, Velizarova, Svetlana, Ferreras-Antolín, Laura, Götzinger, Florian, Bilogortseva, Olga, Chechenyeva, Vira, Tebruegge, Marc, Santiago-García, Begoña, Ptbnet QFT-Plus study group   +34 more
openaire   +7 more sources

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6584-6594, August 2026.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Comparison of PPD and IGST Sensitivity in Latent Tuberculosis Assessment (Cross-sectional Study)

Sakarya Tıp Dergisi
Objective: Purified Protein Derivative (PPD) and Interferon Gamma Release Assay (IGRA) were performed on patients with ankylosing spondylitis and rheumatoid arthritis who were planned to initiate immunosuppressive treatment.
Nurhan Sarıoğlu, Nilay Şahin, Mustafa Çolak, Kazım Batıhan Büyükzengin, Fuat Erel, Hikmet Çoban   +5 more
doaj   +1 more source

A Comparative Policy Review of Tuberculosis Infection Control Policies Across Six Countries: Insights on Screening, Prevention, and Treatment Strategies

Health Science Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background and Aims Tuberculosis (TB) infection remains one of the major global public health challenges, disproportionately affecting vulnerable and marginalized populations. This study aims to compare prevention, screening, and treatment policies for TB in selected countries to identify effective strategies and policy gaps that may inform ...
Mohammad Veysi Sheikhrobat, Sajad Alizadeh, Kamal Shahamiri, Saeed Shahriari, Ahmad Tahmasebi‐Ghorrabi   +4 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Hepatic Sarcoidosis Unmasked by Chronic Pruritus and Esophageal Varices: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Sarcoidosis is a granulomatous disease that affects multiple organs, commonly the liver, with manifestations from asymptomatic disease to cirrhosis and liver failure. A 43‐year‐old male presented with generalized pruritus. Liver biopsy demonstrated findings consistent with sarcoidosis, and treatment was initiated. We emphasize timely follow‐up
Ming Zheng, Keroles Saadalla, Sandipa Sharma   +2 more
wiley   +1 more source

Accuracy of anti-mycobacterial protein 51 antibodies as a biomarker for latent TB infection in asymptomatic HIV positive individuals: a cross-sectional diagnostic study

BMC Research Notes
Objective To evaluate the diagnostic accuracy of anti-Mycobacterial Protein 51 (MPT51) antibodies in latent Tuberculosis (TB) detection among asymptomatic Human Immune Virus (HIV) positive individuals using Interferon Gamma Release Assay (IGRA ...
Josephine Victo Namugga, Carol Musubika, Stuart Niwagaba, Jonathan Mayito, Obondo James Sande   +4 more
doaj   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, Volume 74, Issue 3, Page 636-647, March 2026.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion

Transplant Infectious Disease, Volume 28, Issue 2, March/April 2026.
This study comparing 4‐month rifampin with 9‐month isoniazid for latent tuberculosis in kidney transplant candidates showed higher treatment completion rates and no transaminase elevations in the rifampin group. However, some patients experienced an increase in blood pressure while taking antihypertensive medications known to interact with rifampin ...
Jacques Simkins, Julia Bini Viotti, Yoichiro Natori, Shweta Anjan, Adela Mattiazzi, Mariella Ortigosa‐Goggins, Giselle Guerra, David Roth, Warren Kupin, Javier A. Pagan, Franco Cabeza, Gaetano Ciancio, Mahmoud Morsi, Michele I. Morris   +13 more
wiley   +1 more source